

Marica Eoli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9452882/marica-eoli-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

6,519
citations

32
h-index

79
g-index

136
ext. papers

8,026
ext. citations

5.8
avg, IF

4.54
L-index

#	Paper	IF	Citations
126	Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). <i>Cancers</i> , 2021 , 13,	6.6	8
125	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 831-842	7.4	8
124	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , 2021 , 23, 264-276	1	17
123	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , 2021 , 155, 179-190	7.5	4
122	Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 747690	5.3	1
121	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches.. <i>Cancers</i> , 2021 , 13,	6.6	3
120	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , 2020 , 26, 4478-4484	12.9	5
119	Simultaneous Detection of , , and Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. <i>Genes</i> , 2020 , 11,	4.2	1
118	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020 , 22, 1614-1624	1	18
117	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. <i>Neurological Sciences</i> , 2020 , 41, 2111-2120	3.5	1
116	Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. <i>Human Mutation</i> , 2020 , 41, 299-315	4.7	47
115	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdz051	0.9	6
114	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 684-693	1	62
113	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019 , 21, 1263-1272	1	12
112	Biopsy-proven primary angiitis of the central nervous system mimicking leukodystrophy: A case report and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2019 , 64, 42-44	2.2	7
111	Management of epilepsy in brain tumors. <i>Neurological Sciences</i> , 2019 , 40, 2217-2234	3.5	20
110	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 205-210	4.8	13

109	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz022	0.9	8
108	Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients. <i>Genes</i> , 2019 , 10,	4.2	7
107	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2045-2045	2.2	2
106	Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
105	ABCC3 Expressed by CD56 CD16 NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	9
104	Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. <i>Cancers</i> , 2019 , 11,	6.6	9
103	Neurological malignancies in neurofibromatosis type 1. <i>Current Opinion in Oncology</i> , 2019 , 31, 554-561	4.2	4
102	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019 , 26, 639-650	6	17
101	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019 , 25, 176-183	18.7	88
100	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2019 , 20, 110-119	21.7	116
99	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018 , 102, 69-87	11	93
98	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). <i>Clinical Cancer Research</i> , 2018 , 24, 52-61	12.9	96
97	The noncoding RNA AK127244 in 2p16.3 locus: A new susceptibility region for neuropsychiatric disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018 , 177, 557-562	3.5	3
96	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2023-2023	2.2	10
95	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2047-2047	2.2	3
94	Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14053-e14053	2.2	3
93	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide. <i>OncolImmunology</i> , 2018 , 7, e1412901	7.2	34
92	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2017 , 7, 592-597	3.6	3

91	LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410. <i>Neuro-Oncology</i> , 2017 , 19, vi316-vi316	1	9
90	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2085-TPS2085	2.2	3
89	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
88	Apparent diffusion coefficient (ADC) decrease to predict longer survival in glioblastoma patients treated by dendritic cell immunotherapy plus standard of care.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2065-2065	2.2	0
87	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 279-88	4.8	29
86	Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016 , 39, 37-45; discussion 45-6	3.9	32
85	Clonal evolution of glioblastoma under therapy. <i>Nature Genetics</i> , 2016 , 48, 768-76	36.3	390
84	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 115-20	3.5	22
83	Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2039-2039	2.2	
82	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53
81	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015 , 125, 359-67	4.8	34
80	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 499-504	4.8	26
79	126 novel mutations in Italian patients with neurofibromatosis type 1. <i>Molecular Genetics & Genomic Medicine</i> , 2015 , 3, 513-25	2.3	22
78	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015 , 21, 3307-17	12.9	176
77	Neurofibromatosis Type 1 and Type 2 2015 , 349-354		
76	Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2056-2056	2.2	
75	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13003-e13003	2.2	
74	Fluorescein-guided surgery for malignant gliomas: a review. <i>Neurosurgical Review</i> , 2014 , 37, 547-57	3.9	53

73	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONADO CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.. <i>Neuro-Oncology</i> , 2014 , 16, v143-v144	1	78
72	Is fluorescein-guided technique able to help in resection of high-grade gliomas?. <i>Neurosurgical Focus</i> , 2014 , 36, E5	4.2	106
71	Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. <i>Brain</i> , 2014 , 137, 1907-20	11.2	107
70	Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2087-2087	2.2	1
69	Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. <i>PLoS ONE</i> , 2014 , 9, e90535	3.7	14
68	A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. <i>PLoS ONE</i> , 2014 , 9, e114713	3.7	13
67	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. <i>Acta Neurochirurgica</i> , 2013 , 155, 1277-86	3	100
66	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
65	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. <i>Molecular Cancer</i> , 2013 , 12, 160	42.1	10
64	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>Onc Immunology</i> , 2013 , 2, e23401	7.2	42
63	Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. <i>PLoS ONE</i> , 2013 , 8, e74345	3.7	21
62	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease). <i>Neurological Sciences</i> , 2012 , 33, 1429-33	3.5	1
61	FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 513-28	4.8	23
60	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. <i>Oncotarget</i> , 2012 , 3, 723-34	3.3	69
59	DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. <i>Oncologist</i> , 2011 , 16, 1440-50	5.7	19
58	High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. <i>Molecular Cancer Research</i> , 2009 , 7, 665-77	6.6	78
57	Cisplatin and BCNU chemotherapy in primary glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2009 , 94, 57-62	4.8	17
56	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 61-64	4.8	20

55	Genetic signature of adult gliomas and correlation with MRI features. <i>Expert Review of Molecular Diagnostics</i> , 2009 , 9, 709-20	3.8	11
54	Molecular Markers of Gliomas 2009 , 157-177		
53	Tumori cerebrali 2009 , 297-314		
52	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2008 , 87, 143-51	4.8	29
51	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <i>Journal of Neuro-Oncology</i> , 2008 , 88, 105-13	4.8	31
50	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. <i>Journal of Neuro-Oncology</i> , 2007 , 82, 273-9	4.8	15
49	Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. <i>Clinical Cancer Research</i> , 2007 , 13, 2606-13	12.9	123
48	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006 , 119, 84-90	7.5	39
47	Molecular markers of gliomas: a clinical approach. <i>Neurological Research</i> , 2006 , 28, 538-41	2.7	4
46	Local drug delivery in recurrent malignant gliomas. <i>Neurological Sciences</i> , 2005 , 26 Suppl 1, S37-9	3.5	16
45	The role of the neurologist. <i>Neurological Sciences</i> , 2005 , 26 Suppl 1, S46-8	3.5	
44	Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. <i>Journal of Neuro-Oncology</i> , 2005 , 71, 271-6	4.8	19
43	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005 , 72, 125-31	4.8	36
42	Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005 , 74, 87-9	4.8	23
41	CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. <i>Journal of Neuro-Oncology</i> , 2005 , 74, 287-93	4.8	47
40	Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005 , 75, 215-20	4.8	15
39	Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2004 , 66, 203-8	4.8	54
38	CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. <i>Journal of Neuro-Oncology</i> , 2004 , 67, 305-17	4.8	60

37	Headache in brain tumours: a symptom to reappraise critically. <i>Neurological Sciences</i> , 2004 , 25 Suppl 3, S143-7	3.5	24
36	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. <i>Neuroscience Letters</i> , 2004 , 370, 180-5	3.3	45
35	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2003 , 62, 297-303	4.8	121
34	Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. <i>Neurological Sciences</i> , 2003 , 24, 272	3.5	4
33	Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. <i>Journal of Neurosurgery</i> , 2003 , 98, 935-6; author reply 936	3.2	2
32	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002 , 52, 842-5	9.4	29
31	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. <i>Neurological Sciences</i> , 2002 , 23, 219-24	3.5	23
30	Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. <i>Neurological Sciences</i> , 2002 , 23, 257-8	3.5	9
29	Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. <i>Journal of Neuro-Oncology</i> , 2001 , 54, 39-47	4.8	18
28	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. <i>Journal of Neuro-Oncology</i> , 2000 , 49, 71-5	4.8	9
27	Embryonal tumors in the adult population: implications in therapeutic planning. <i>Neurological Sciences</i> , 2000 , 21, 23-30	3.5	9
26	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. <i>Neuromuscular Disorders</i> , 2000 , 10, 391-7	2.9	86
25	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 178-9	3.5	13
24	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. <i>Italian Journal of Neurological Sciences</i> , 1999 , 20, 43-8		23
23	Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. <i>Cancer Letters</i> , 1999 , 146, 169-72	9.9	19
22	Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. <i>Italian Journal of Neurological Sciences</i> , 1998 , 19, 32-6		15
21	Meningo-cortical calcifying angiomatosis and celiac disease. <i>Clinical Neurology and Neurosurgery</i> , 1998 , 100, 209-15	2	8
20	Immunological monitoring of azathioprine treatment in multiple sclerosis patients. <i>Journal of Neurology</i> , 1997 , 244, 167-74	5.5	17

19	Parallel fluctuations of psychiatric and neurological symptoms in a patient with multiple sclerosis and bipolar affective disorder. <i>Italian Journal of Neurological Sciences</i> , 1995 , 16, 551-3		6
18	Racemose neurocysticercosis after chronic meningitis: effect of medical treatment. <i>Clinical Neurology and Neurosurgery</i> , 1995 , 97, 50-4	2	9
17	Analysis of HLA-class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients. <i>International Journal of Immunogenetics</i> , 1995 , 22, 171-8		12
16	Evidence of linkage between susceptibility to multiple sclerosis and HLA-class II loci in Italian multiplex families. <i>European Journal of Human Genetics</i> , 1995 , 3, 303-11	5.3	12
15	Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. <i>European Neurology</i> , 1994 , 34, 199-203	2.1	68
14	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. <i>Italian Journal of Neurological Sciences</i> , 1994 , 15, 333-40		18
13	The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients. <i>Journal of Neurology</i> , 1994 , 241, 615-9	5.5	17
12	No linkage between multiple sclerosis and the T cell receptor alpha chain locus. <i>Journal of the Neurological Sciences</i> , 1994 , 124, 32-7	3.2	11
11	Phenotype analysis of unstimulated lymphocytes and anti-CD3-stimulated proliferating T-cells from cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and other neurological diseases. <i>International Journal of Neuroscience</i> , 1993 , 73, 277-85	2	4
10	A double blind study on azathioprine efficacy in multiple sclerosis: final report. <i>Journal of Neurology</i> , 1993 , 240, 295-8	5.5	33
9	Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity. <i>Journal of Neurology</i> , 1993 , 240, 79-82	5.5	14
8	Short-term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 107-12		5
7	HLA antigens in Italian multiple sclerosis patients. <i>Italian Journal of Neurological Sciences</i> , 1991 , 12, 81-6		9
6	HLA and multiple sclerosis in Italy: a review of the literature. <i>Journal of Neurology</i> , 1990 , 237, 441-4	5.5	7
5	Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990 , 53, 554-7	5.5	20
4	Role of physical training on immune function: preliminary data. <i>International Journal of Neuroscience</i> , 1990 , 51, 249-52	2	3
3	Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. <i>European Neurology</i> , 1989 , 29, 10-4	2.1	41
2	CSF T-cell subsets in multiple sclerosis: relationship to cerebrospinal fluid myelin basic protein and clinical activity. <i>Journal of Neurology</i> , 1989 , 236, 336-9	5.5	12

- 1 Cryoglobulinemic neuropathy: case report. *Italian Journal of Neurological Sciences*, **1988**, 9, 391-5

1